Multiple sclerosis (MS) is a complex, heterogeneous, chronic disease that requires individualized treatment throughout a patient’s life. The disease involves the central nervous system and disrupts the flow of information within the brain and between the brain and body, signaling unpredictable symptoms.¹

Over the past four decades, Biogen has been committed to translating science to meaningful advances for the MS community. Our industry-leading portfolio — backed by established safety and efficacy profiles, ongoing investment in our products, as well as our comprehensive services and solutions — enables us to offer a broad range of options to meet the ever-evolving needs of MS patients and drive greater individualized disease management.

As MS disease management and patient needs evolve, Biogen remains focused on novel research initiatives and technological innovations to further the understanding of MS and improve patient outcomes. While we focus on advancing current assets in our pipeline, we aspire to pioneer disruptive therapies for MS prevention and cure through exploration in emerging science, including novel treatment approaches such as vaccine cell-based therapies, exploring new mechanisms of remyelination and neuroprotection, and developing additional preclinical models that have enhanced translational predictability.